Literature DB >> 18226732

Acromegaly.

Anat Ben-Shlomo1, Shlomo Melmed.   

Abstract

Acromegaly is caused by growth hormone hypersecretion, mostly from a pituitary adenoma, driving insulin-like growth factor 1 overproduction. Manifestations include skeletal and soft tissue growth and deformities; and cardiac, respiratory, neuromuscular, endocrine, and metabolic complications. Increased morbidity and mortality require early and tight disease control. Surgery is the treatment of choice for microadenomas and well-defined intrasellar macroadenomas. Complete resection of large and invasive macroadenomas rarely is achieved; hence, their low rate of disease remission. Pharmacologic treatments, including long-acting somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, have assumed more importance in achieving biochemical and symptomatic disease control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226732      PMCID: PMC2697616          DOI: 10.1016/j.ecl.2007.10.002

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  154 in total

Review 1.  Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

2.  Rational design of potent antagonists to the human growth hormone receptor.

Authors:  G Fuh; B C Cunningham; R Fukunaga; S Nagata; D V Goeddel; J A Wells
Journal:  Science       Date:  1992-06-19       Impact factor: 47.728

3.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

Review 4.  Does growth hormone cause cancer?

Authors:  P J Jenkins; A Mukherjee; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  2006-02       Impact factor: 3.478

5.  Arrhythmia profile in acromegaly.

Authors:  G Kahaly; K V Olshausen; S Mohr-Kahaly; R Erbel; S Boor; J Beyer; J Meyer
Journal:  Eur Heart J       Date:  1992-01       Impact factor: 29.983

6.  Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.

Authors:  P J Jenkins; V Frajese; A M Jones; C Camacho-Hubner; D G Lowe; P D Fairclough; S L Chew; A B Grossman; J P Monson; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

Review 7.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

8.  The pathology of median neuropathy in acromegaly.

Authors:  P J Jenkins; S A Sohaib; S Akker; R R Phillips; K Spillane; J A Wass; J P Monson; A B Grossman; G M Besser; R H Reznek
Journal:  Ann Intern Med       Date:  2000-08-01       Impact factor: 25.391

9.  Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.

Authors:  Pamela U Freda; Abu T Nuruzzaman; Carlos M Reyes; Robert E Sundeen; Kalmon D Post
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

10.  Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors.

Authors:  Giovanna Mantovani; Sara Bondioni; Andrea G Lania; Sabrina Corbetta; Luisa de Sanctis; Marco Cappa; Eliana Di Battista; Philippe Chanson; Paolo Beck-Peccoz; Anna Spada
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

View more
  45 in total

1.  Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters.

Authors:  L Vannucci; P Luciani; E Gagliardi; S Paiano; R Duranti; G Forti; A Peri
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

Review 2.  Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature.

Authors:  Reshma Shah; Angelo Licata; Nelson M Oyesiku; Adriana G Ioachimescu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients.

Authors:  Serpil Yazgan; Dilek Arpaci; Haci Ugur Celik; Irem Isik
Journal:  Int Ophthalmol       Date:  2017-05-15       Impact factor: 2.031

4.  Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.

Authors:  F Bogazzi; G Rossi; M Lombardi; F Raggi; C Urbani; C Sardella; C Cosci; E Martino
Journal:  J Endocrinol Invest       Date:  2010-07-29       Impact factor: 4.256

5.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

6.  Safety and efficacy of repeat radiosurgery for acromegaly: an International Multi-Institutional Study.

Authors:  Clayton E Alonso; Adomas Bunevicius; Daniel M Trifiletti; James Larner; Cheng-Chia Lee; Fu-Yuan Pai; Roman Liscak; Mikulas Kosak; Hideyuki Kano; Nathaniel D Sisterson; David Mathieu; L Dade Lunsford; Jason P Sheehan
Journal:  J Neurooncol       Date:  2019-09-20       Impact factor: 4.130

7.  Antiproliferative effects of somatostatin analogs in endocrine tumours.

Authors:  Maria Chiara Zatelli
Journal:  F1000 Med Rep       Date:  2009-05-08

8.  A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene in an Italian family with gigantism.

Authors:  C Urbani; D Russo; F Raggi; M Lombardi; C Sardella; I Scattina; I Lupi; L Manetti; L Tomisti; C Marcocci; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2014-07-05       Impact factor: 4.256

Review 9.  Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886).

Authors:  Wouter W de Herder
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.